Bronchiectasis: Still a problem

Chinese Medical Journal

Volumn 127, Issue 1, 2014, Pages 157-172

  Wang, Zeng Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bronchiectasis; Burden; Management; Prevalence

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; AZD 9668; AZITHROMYCIN; CIPROFLOXACIN; CORTICOSTEROID; ERYTHROMYCIN; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO;

BACTERIAL VIRULENCE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; LUNG FUNCTION; MORBIDITY; MORTALITY; MUCOCILIARY CLEARANCE; NEUTROPHIL; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR;

BRONCHIECTASIS; HUMANS;

EID: 84891669612     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132165     Document Type: Review

References (103)

1. Feldman C. Bronchiectasis: why the diagnosis shouldn't be missed in primary care. Prim Care Respir J 2011; 20: 107-108.
2. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009; 14: 637-650.
3. Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005; 90: 737-740.
4. De Soyza A, Brown JS, Loebinger MR. On behalf of the bronchiectasis research and academic network. Research priorities in bronchiectasis. Thorax 2013; 68: 695-696.
5. Eastham KM, Fall AJ, Mitchell L, Spencer DA. The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax 2004; 59: 324-327.
6. Chang AB, Bell SC, Byrmes CA, Grimwood K, Holmes PW, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010; 193: 356-365.
7. Bilton D, Jones AL. Bronchiectasis: epidemiology and causes. Eur Respir Mon 2011; 52: 1-10.
8. Weycker D, Edelsberg J, Oster D, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12: 205-209.
9. King PT, Daviskas E. Pathogenesis and diagnosis of bronchiectasis. Breathe 2010; 6: 343-351.
10. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tubercul Lung Dis 2004; 8: 691-702.
11. Athanazio R. Airway disease: similarities and differences between asthma, COPD and bronchiectasis. Clinics 2012; 67: 1335-1343.
12. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006; 35: 58-65.
13. Hill AT, PasteurM, Cornford C, Welham S, Bilton D. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20: 135-140.
14. Seitz AE, Olivier KN, Adjemian J, Holland SM. Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142: 432-439.
15. Roberts ME, Lowndes L, Milne DE, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Int Med J 2011; 2: 129-136.
16. Seitz AE, Oliver KN, Steiner CA, De Doa RM, Holland SM, Prevors R, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138: 944-949.
17. Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 2012; 141: 1018-1024.
18. O'Donnell AE. Bronchiectasis. Chest 2008; 134: 815-823.
19. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010; 15: 623-628.
20. Vendroll M, de Gracia J, Rodyigo MJ. Cruz MJ. Awarez ZA, Garcie M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005; 127; 197-204.
21. Philpott CM, Mekierna DC. Bronchiectasis and sinonasal disease: a review. J Laryn Otol 2008; 122; 11-15.
22. Fledman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med 2011; 32; 535-546.
23. Iiowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis 2008; 21: 163-167.
24. Loebinger MR, Wells AV, Hansell DM, Chinyanganya N, Doveraj A, Master M, et al. Mortality in bronchiectasis: a long-term study assessing the factor influencing survival. Eur Respir J 2009; 34; 843-849.
25. Al-shirawi N, Al-Jahdall MH, Alshimemeri A. Pathogenesis, etiology and treatment of bronchiectasis. Ann Thorac Med 2006; 1: 41-51.
26. Pasteur MC, Bitton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: i1-i58.
27. Shoemark A, Ozeravith L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163-1170.
28. Mc Shane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population. Effects of ethnicity on etiology and sputum culture. Chest 2012; 142: 159-167.
29. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008; 14: 595-599.
30. Parr DG, Guest PE, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in a1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176; 1215-1221.
31. Dhasmana DJ, Wilson R. Bronchiectasis and autoimmune disease. Eur Respir Mon 2011; 52: 192-210.
32. Laebinger MR, Bilton D, Wilson R. Upper airway2: bronchiec-bronchiectasis, cystic fibrosis and sinositis. Thorax 2009; 64: 1096-1101.
33. Bienvenu T, Sermet-Gaudelus I, Burgel PR, Hubert D, Crestan D, CrestaniB, Bassinet L, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181: 1078-1084.
34. Rezende Goncalves J, Corso Peceira M, De Cerqueira EM, Oliverira Magro D, Mello Moreira M, Paschoal IA. Severe obstructive disease: similarities and differences between smoker and non-smoker patients with COPD and /or bronchiectasis. Rev Port Pneumol 2013; 19: 13-18.
35. Mandal P, Mill AT. Bronchiectasis: breaking the cycle of inflammation and infection. Lancet Respir Med 2013; 1: e5-e6.
36. Goddard M. Histopathology of bronchiectasis. Eur Respir Mon 2011; 52: 22-31.
37. King PT. The pathophysiology of bronchiectasis. Int J COPD 2009; 28: 289-296.
38. Zoumot Z, Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis 2010; 23: 165-170.
39. Morrisy BM. Pathogenesis of bronchiectasis. Clin Chest Med 2007; 28: 289-296.
40. Lambrecht BN, Neyt K, Geurtsvankessel CH. Pulmonary defence mechanisms and inflammatory pathways in bronchiectasis. Eur Respir Mon 2011; 52: 11-21.
41. Farley AH, Hendry C, Johnstone C. Bronchiectasis: pathophysiology, presentation and management. Nursing Standard 2008; 83: 50-56.
42. Boyton RJ. Altmann DM. Immune regulation in idiopathic bronchiectasis. Ann NY Acad Sci 2012; 1272: 68-72.
43. Voglis S, Quinn K, Tullis E, Liu M, Henrigues M, Zubrinich C, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectasis. Am J Respir Crit Care Med 2009; 180: 159-166.
44. Anwar GA, Mc Dannell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013; 109: 1001-1007.
45. Davies G, Wells AV, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006; 28: 974-979.
46. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383-1393.
47. Marris JK, Zemanick ET. Microbe in bronchiectasis: the forest or the trees? Am J Respir Crit Care Med 2013; 187: 1044-1045.
48. Tunney MH, Einarsson GG, Wei L, Drain M, Kleim ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 189: 1118-1126.
49. Rogers GB, vander Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult man. CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68: 731-737.
50. Kim WJ, Hoffman E, Reilly J, Nersh C, Demes D. Washco G, et al. Association of COPD candidate genes with CT emphysema and airway phenotypes in severe COPD. Eur Respir J 2011; 37: 39-43.
51. Notarangelo LD, Plobani A, Mazzolari E, Soresina A, Bondioni MP. Genetic causes of bronchiectasis: primary immune deficiencies and lung. Respiration 2009; 74: 264-275.
52. Morillas HN, Zariwala M, Knowles MR. Genetic causes of bronchiectasis: primary ciliary dyskinesia. Respiration 2007; 74: 252-263.
53. Han ML, Huang YJ, Lipuma JJ, Boushey HA, Boucher RC. Cookson WO, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012; 67: 456-463.
54. Driscoll JA, Bhalla S, Liapis H, Ibrirevic A, Brody SL. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008; 133: 1181-1188.
55. Stockley RA. Bronchiectasis with chronic obstructive pulmonary disease. Association or a further phenotype? Am J Respir Crit Care Med 2012; 187: 786-788.
56. Patel IS, Vlahos I, Wilkinson TMA, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400-407.
57. Habesoglu HA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Ann Thorac Med 2011; 6: 131-136.
58. Novosad SA, Barker AF. Chronic obstructive pulmonary disease and bronchiectasis. Curr Opin Pulm Med 2013; 19: 133-139.
59. King PT, Holdworth S, Farmer MW, Freezer N, Villanueva E, Holmes P. Phenotypes of bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009; 6: 130-136.
60. Martinez-Garcia MA, de la Rosa Carrillo D, Solor-cataluma JJ, Donal-SamZY, Serra PC, Lerma MA, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831.
61. Truong T. The overlap of bronchiectasis and immunodeficiency with asthma. Immunol Allergy Clin N Am 2013; 33: 61-78.
62. Zimmer J, Sleiman M, Poli A, Michel T, Hentges F. TAP deficiency is also a cause of bronchiectasis. Thorax 2013; 68: 490-491.
63. Pfeffer PE, Nawrylowicz CH. Vitamin D and lung disease. Thorax 2012; 67: 1018-1020.
64. Chalmers JD, McHugh BJ, Docherty C, Govan JRW, Hill AT. Vitamin D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68: 39-47.
65. Shee C. Is hypovitaminosis D a consequence rather than cause of disease? Thorax 2013; 68: 679.
66. Chalmers JD. Author response-vitamin D deficiency and systemic inflammation in bronchiectasis. Thorax 2013; 68: 679.
67. Bonavita J, Naidich DP. Imaging of bronchiectasis. Clin Chest Med 2012; 32: 233-248.
68. Cantin L, Bankier AA, Eisenberg RL. Bronchiectasis AJR 2009; 193: w158-w171.
69. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med 2010; 86: 493-501.
70. Dariskas E, Rubin BK. The effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013; 7: 65-72.
71. Gjoerup J, Hilberg O, Bendstrup E. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 2012; 17: 927-932.
72. Bye PT. Lau EMT, Elkins MR. Pharmacological airway clearance strategies in bronchiectasis. Eur Respir J Mon 2011; 52: 239-247.
73. Dariskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the suptum properties in bronchiectasis. Respir Med 2010; 104: 371-377.
74. Bilton D, Daviskas E, Biomad E, Anderson SD, Kelbe J, King G, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225.
75. Nicolson CHH, Stirling RG, Borg MA, Button BM, Wilson JW, Holl AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667.
76. Stockley R, DeSoyza A, Gunawardena K, Perrett J, Forsman-Semh K, Entwistle N, et al. Phase II study of a neutrophil elastase inhibitor (AZD 9668) in patients with bronchiectasis. Respir Med 2013; 109: 524-533.
77. Smith DJ, Chang AB, Bell SC. Anti-inflammation therapies in bronchiectasis. Eur Respir J Mon 2011; 52: 223-228.
78. Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence based clinical practice guidelines. Chest 2006; 129: 1225-1315.
79. Kolbe J, Wells A, Ram FS. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; (2): CD000996.
80. Laebinger MR, Wilson R. Pharmacotherapy for bronchiectasis. Expert Opin Pharmacother 2007; 8: 3183-3193.
81. Tsang KW, Tam KC, Ho PL, Oi GC, HoJC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60: 239-243.
82. Guran T, Ersu R, Karadag B, Karakoc F, Demiral GY, Hekim N, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Phar Therap 2008; 33: 603-611.
83. Metersky ML. New treatment option for bronchiectasis. Ther Adv Respir Dis 2010; 4: 93-99.
84. Yamaya M, Azuma A, Takizawa H, Kedota J, Tamaoki J, Kudoh S. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494.
85. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013; 42: 239-251.
86. Simaens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med 2013; 107: 637-648.
87. Murray MP, Turnbull K, MacQuarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33: 312-317.
88. Babu KS, Kastelik J, Morjaria JB. Role of long term antibiotics in chronic respiratory diseases. Respir Med 2013; 107: 800-815.
89. Rademacher J, Ringshausen. Prevention and treatment of exacerbation of non-CF bronchiectasis. Eur Respir Mon 2013; 60: 127-136.
90. Mandall P, Sidhu MK, Donaldson LS, Chalmers JD, Smith MP, Turnbull K, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013; 106: 27-33.
91. Smith MP, Hill AT. Evaluating success of therapy for bronchi-bronchiectasis. What end points to use? Clin Chest Med 2012; 33: 329-349.
92. Chalmers JD, Smith MP, Mehugh BJ, Doherty C, Govan JR, Hill AT. Short and long term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
93. Brown JT, Hill AT. Macrolides and pneumonia. Thorax 2013; 68: 404-405.
94. Liu JF, Zhong XA, He ZY, Zhong DJ, Bai J, Zhang JQ, et al. Impact of treatment with low dose roxithromycin on stable bronchiectasis (in Chinese). Chin J Tuberc Respir Dis 2012; 35: 824-827.
95. Wan ZH, Fan H, Hu K, Yu HY, Chew GZ, Hu SP. Efficacy of long-term inhaled Salmeterol/Fluticasone combined with low dose oral erythromycin in patients with bronchiectasis (in Chinese). Chin J Respir Crit Care Med 2012; 11: 371-374.
96. Wong C, Jayaram L, Karalu N, Eaton T, CeciliaT, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double blind, placebo-controlled trial. Lancet 2012; 380: 1329-1334.
97. Serisier DJ, Martin ML, McGuction MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013; 309: 1260-1267.
98. Wilson R, Welfe T, Polverino E, DeSoyza A, Greville H, O'Donnel A, et al. Ciprofloxacin dry powder inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1109.
99. Serisier DJ, Bilton D, Desoyza A, Thomyson PJ, Kolbe J, Greville HW, et al. Inhaled dual release liposomal ciprofloxacin in non cystis fibrosis bronchiectasis (ORBIT-2): a randomised double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817.
100. Balkanli K, Geng O, Dakak M, Gurkok S, Goziiyiik A, Caylak H, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiovasc Surg 2003; 23: 699-702.
101. Wang GS, Wang Z, Lin SL. Thoracoscopic management for bronchiectasis with non-tuberculous mycobacterial infection. Chin Med J 2008; 121: 2539-2543.
102. Zhou ZL, Zhao H, Li Y, Li JF, Jiang GC, Wang J. Completely thoracoscopic lobectomy for the surgical management of bronchiectasis. Chin Med J 2013; 126: 875-878.
103. Oh THT, Wang TKM, Ramming J, Ramanathan T. First elective thoracic endovascular aortic repair to treat hemoptysis due to bronchiectasis. Am J Respir Crit Care Med 2013; 188: 517-519.